Clinical Trial Update: Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2a study to assess safety, pharmacokinetics, pharmacodynamics, tolerability and the effect on body weight of RN3161 as monotherapy and in combination …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• MOUNJARO (tirzepatide)
• RN3161

Snippet

Sponsor: Ikaria Bioscience Pty Ltd | Conditions: Obesity &Amp; Overweight | Phase 1, Phase 2 | Status: RECRUITING